Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Service and Laboratory of Nephrology, Department of Internal Medicine Specialties and.
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):435-444. doi: 10.2215/CJN.02240218. Epub 2018 May 29.
The success of combination antiretroviral therapy in the treatment of HIV-1-positive individuals has shifted clinical attention toward combination antiretroviral drug regimens that optimize tolerability, long-term safety, and durable efficacy. Wherever patients have access to treatment, morbidity and mortality are increasingly driven by non-HIV-associated comorbidities, which may be observed earlier than in age-matched controls and despite the best available combination antiretroviral therapy. Similarly, HIV-1-positive individuals are now diagnosed and treated earlier with anticipated lifelong therapy. The contribution of specific antiretroviral agents to long-term morbidity and mortality is dependent on the pharmacologic characteristics of these agents, and it is increasingly important in this context.
联合抗逆转录病毒疗法在治疗 HIV-1 阳性个体方面的成功，使临床注意力转向了优化耐受性、长期安全性和持久疗效的联合抗逆转录病毒药物方案。无论患者在哪里获得治疗，发病率和死亡率越来越受到非 HIV 相关合并症的驱动，这些合并症可能比年龄匹配的对照组更早出现，尽管采用了最佳的联合抗逆转录病毒治疗。同样，HIV-1 阳性个体现在更早地被诊断和治疗，并预期接受终身治疗。特定抗逆转录病毒药物对长期发病率和死亡率的贡献取决于这些药物的药理特性，这在当前的背景下变得越来越重要。
